12,427 Shares in Revvity, Inc. (NYSE:RVTY) Acquired by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd bought a new position in shares of Revvity, Inc. (NYSE:RVTY) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 12,427 shares of the company’s stock, valued at approximately $1,358,000.

Other hedge funds have also added to or reduced their stakes in the company. KBC Group NV bought a new stake in shares of Revvity in the 3rd quarter valued at $25,301,000. 2Xideas AG bought a new stake in shares of Revvity in the 3rd quarter valued at $20,968,000. Citigroup Inc. bought a new stake in Revvity during the 3rd quarter valued at $5,548,000. Wesbanco Bank Inc. bought a new stake in Revvity during the 3rd quarter valued at $522,000. Finally, Headinvest LLC bought a new stake in Revvity during the 3rd quarter valued at $57,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Trading Down 0.8 %

Shares of Revvity stock opened at $102.68 on Thursday. Revvity, Inc. has a 12-month low of $79.50 and a 12-month high of $133.26. The company has a market cap of $12.68 billion, a price-to-earnings ratio of 18.67, a PEG ratio of 2.69 and a beta of 1.09. The company has a current ratio of 2.07, a quick ratio of 1.77 and a debt-to-equity ratio of 0.40. The company’s 50-day moving average price is $104.72 and its 200-day moving average price is $101.50.

Revvity (NYSE:RVTY) last announced its earnings results on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.15 by $0.10. The business had revenue of $695.90 million for the quarter. Revvity had a net margin of 25.20% and a return on equity of 7.41%. On average, equities analysts expect that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the transaction, the insider now directly owns 92,801 shares in the company, valued at $9,677,288.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.60% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on RVTY shares. Raymond James boosted their price target on shares of Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Stifel Nicolaus boosted their price target on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. UBS Group downgraded shares of Revvity from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $105.00 to $125.00 in a report on Tuesday, January 16th. Barclays lifted their price objective on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Finally, KeyCorp lifted their price objective on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $118.91.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.